Ken-ichi Kusakabe

List of Publications by Year
in descending order

21	597	687363 13	752698 20
papers	citations	h-index	g-index

22	22	22	633
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020). Expert Opinion on Therapeutic Patents, 2021, 31, 25-52.	5.0	22
2	Facile Construction of an Amino-1,3-Oxazine Scaffold using Burgess Reagent Under Mild Conditions. Tetrahedron Letters, 2021, 64, 152684.	1.4	1
3	Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based Î²-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial. Journal of Medicinal Chemistry, 2021, 64, 1873-1888.	6.4	30
4	Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective Î²-Secretase (BACE1) Inhibitors over BACE2. Journal of Medicinal Chemistry, 2021, 64, 3075-3085.	6.4	11
5	Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central AÎ² reduction. European Journal of Medicinal Chemistry, 2021, 216, 113270.	5.5	7
6	JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. Journal of Medicinal Chemistry, 2021, 64, 14175-14191.	6.4	10
7	Discovery of Extremely Selective Fused Pyridine-Derived Î²-Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions. Journal of Medicinal Chemistry, 2021, 64, 14165-14174.	6.4	4
8	Trifluoromethyl Dihydrothiazineâ€Based Î²â€Secretase (BACE1) Inhibitors with Robust Central Î²â€Amyloid Reduction and Minimal Covalent Binding Burden. ChemMedChem, 2019, 14, 1894-1910.	3.2	8
9	Discovery of an Extremely Potent Thiazine-Based Î²-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose. Journal of Medicinal Chemistry, 2019, 62, 9331-9337.	6.4	7
10	Structure-Based Design of Selective Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2. Journal of Medicinal Chemistry, 2019, 62, 5080-5095.	6.4	29
11	Synthesis of a 6-CF₃-Substituted 2-Amino-dihydro-1,3-thiazine Î²-Secretase Inhibitor by N,N-Diethylaminosulfur Trifluoride-Mediated Chemoselective Cyclization. Journal of Organic Chemistry, 2019, 84, 4893-4897.	3.2	11
12	Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine Î²-Secretase (BACE1) Inhibitors via Active Conformation Stabilization. Journal of Medicinal Chemistry, 2018, 61, 5525-5546.	6.4	28
13	Rational Design of Novel 1,3-Oxazine Based Î²-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust AÎ² Reduction in the Brain. Journal of Medicinal Chemistry, 2018, 61, 5122-5137.	6.4	29
14	Discovery of Imidazo[1,2-b]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity. Journal of Medicinal Chemistry, 2015, 58, 1760-1775.	6.4	61
15	A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. Bioorganic and Medicinal Chemistry, 2015, 23, 2247-2260.	3.0	15
16	Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists. Bioorganic and Medicinal Chemistry, 2013, 21, 2045-2055.	3.0	32
17	Indazole-Based Potent and Cell-Active Mps1 Kinase Inhibitors: Rational Design from Pan-Kinase Inhibitor Anthrapyrazolone (SP600125). Journal of Medicinal Chemistry, 2013, 56, 4343-4356.	6.4	39
18	Selective CB2 agonists with anti-pruritic activity: Discovery of potent and orally available bicyclic 2-pyridones. Bioorganic and Medicinal Chemistry, 2013, 21, 3154-3163.	3.0	16

#	Article	IF	Citations
19	Diaminopyridine-Based Potent and Selective Mps1 Kinase Inhibitors Binding to an Unusual Flipped-Peptide Conformation. ACS Medicinal Chemistry Letters, 2012, 3, 560-564.	2.8	31
20	Chiral Catalyst Optimization Using Both Solid-Phase and Liquid-Phase Methods in Asymmetric Aza Dielsâ˜Alder Reactions. Organic Letters, 2000, 2, 1225-1227.	4.6	94
21	A Switch of Enantiofacial Selectivities Using Designed Similar Chiral Ligands in Zirconium-Catalyzed Asymmetric Aza Dielsâ˜Alder Reactions. Journal of Organic Chemistry, 1999, 64, 4220-4221.	3.2	112